Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abemaciclib and 5-Fluorouracil in Metastatic, Refractory Colorectal Cancer
NCT06654037Phase 1Recruiting
- Sponsor
- National Cancer Institute
- Start
- Apr 2025
- Primary completion
- Apr 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of abemaciclib in colorectal cancer (CRC), sponsored by National Cancer Institute. Primary endpoints: Dose-limiting toxicity at 28 days, Maximum tolerated dose and 1 more. Started Apr 2025; status: recruiting.
02
Drugs
abemaciclib
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT06654037.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06654037.